Cannabis Companies Push F.D.A. to Ease Rules on CBD Products

June 7, 2019

(New York Times) – The F.D.A. has been skeptical of the rapidly growing cannabis industry, but it is under increasing pressure from Congress to ease the path to market for cannabis-derived products. These products are different from medical marijuana, which a growing number of states allow for treating severe pain, nausea and other ailments. Conservative estimates predict that sales of CBD in the United States could be $16 billion by 2025.

Recommended Reading